SLC2A1 Variants and Diabetic Nephropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01768611|
Recruitment Status : Completed
First Posted : January 15, 2013
Last Update Posted : January 16, 2013
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||449 participants|
|Official Title:||Association of Single Nucleotide Polymorphisms in the Gene Coding GLUT-1 and Diabetic Nephropathy in Brazilian Patients With Type 1 Diabetes Mellitus|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
Withou Diabetic Nephropathy
Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
Overt Diabetic Nephropathy
Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
- Plasmatic Creatinine [ Time Frame: Two years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01768611
|Faculdade de Medicina da USP|
|São Paulo, SP, Brazil, 01246-000|
|Principal Investigator:||Maria L Côrrea-Giannela, Doctor||Hospital Clínicas/Faculdade de Medicina da USP|